FOLFIRINOX treatment

Phase 2Small molecule

CCentre Georges Francois Leclerc

FOLFIRINOX treatment is one of 67 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Byetta

1 3

FOLFIRINOX treatment

CCentre Georges Francois Leclerc

Phase 2

1 4

ABI-007

Bristol-Myers Squibb

Preclinical

2 5

LDE225

Novartis

Preclinical

1 6

Sulfonylureas

Eli Lilly

Preclinical

1 7

Thiazolidinediones

Sanofi

Preclinical

1 8

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 9

Meglitinides

Sanofi

Preclinical

1 10

Secretin-Ferring

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Pancreatic Cancer

NCT05988814

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

Active, not recruiting·CCentre Georges Francois Leclerc·Phase 1/2·NCT03795311·32 enrolled

Pancreatic Cancer1 trial

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Recruiting·CCentre Georges Francois Leclerc·Phase 2·NCT05988814·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FOLFIRINOX treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFIRINOX treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFIRINOX treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Georges Francois Leclerc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCentre Georges Francois Leclerc

FOLFIRINOX treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Colorectal Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News